Heterogeneity of CD40 Expression in Different Types of High-Risk Endometrial Cancer Affects Discordant Prognostic Outcomes

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a national cancer database analysis. Int J Gynecol Cancer. 2017;27(1):85–92. doi:10.1097/IGC.0000000000000844
   PubMed Web of Science ®Google Scholar
• Ma HS, Poudel B, Torres ER, et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of Nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res. 2019;7(3):428–442.
   PubMed Web of Science ®Google Scholar
• Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Immune checkpoint inhibitors for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2022;22(3):249–258. doi:10.1080/14737140.2022.2044311
   PubMed Web of Science ®Google Scholar
• Baxendale AJ, Dawson CW, Stewart SE, et al. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene. 2005;24(53):7913–7923. doi:10.1038/sj.onc.1208929
   PubMed Web of Science ®Google Scholar
• Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017;145(1):200–207. doi:10.1016/j.ygyno.2016.12.015
   PubMed Web of Science ®Google Scholar
• Yoon HH, Jin Z, Kour O, et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 Phase 3 randomized clinical trials. JAMA Oncol. 2022;8(10):1456–1465. doi:10.1001/jamaoncol.2022.3707
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19(5):287–305.
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–761. doi:10.1200/JCO.21.01874
   PubMed Web of Science ®Google Scholar
• Kim J, Noh JJ, Lee TK, et al. Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: a multicenter study in Korea. Gynecol Oncol. 2022;165(2):369–375. doi:10.1016/j.ygyno.2022.02.020
   PubMed Web of Science ®Google Scholar
• Jones NL, Xiu J, Rocconi RP, Herzog TJ, Winer IS. Immune checkpoint expression, microsatellite instability, and mutational burden: identifying immune biomarker phenotypes in uterine cancer. Gynecol Oncol. 2020;156(2):393–399. doi:10.1016/j.ygyno.2019.11.035
   PubMed Web of Science ®Google Scholar
• Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570–1573. doi:10.1158/2326-6066.CIR-19-0149
   PubMed Web of Science ®Google Scholar
• Zong L, Sun Z, Mo S, et al. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer. Gynecol Oncol. 2021;162(3):631–637. doi:10.1016/j.ygyno.2021.07.009
   PubMed Web of Science ®Google Scholar
• Mamat Yusof MN, Chew KT, Kampan N, et al. PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis. Cancers. 2022;14(16):3911. doi:10.3390/cancers14163911
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu Rev Med. 2020;71:47–58. doi:10.1146/annurev-med-062518-045435
   PubMed Web of Science ®Google Scholar
• Weiss SA, Djureinovic D, Jessel S, et al. A Phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1/PD-L1. Clin Cancer Res. 2021;27(17):4757–4767. doi:10.1158/1078-0432.CCR-21-0903
   PubMed Web of Science ®Google Scholar
• Diggs LP, Ruf B, Ma C, et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J Hepatol. 2021;74(5):1145–1154. doi:10.1016/j.jhep.2020.11.037
   PubMed Web of Science ®Google Scholar
• Garris CS, Wong JL, Ravetch JV, Knorr DA. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Sci Transl Med. 2021;13(594):eabd1346. doi:10.1126/scitranslmed.abd1346
   PubMed Web of Science ®Google Scholar
• Yan C, Richmond A. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. Mol Cancer. 2021;20(1):146. doi:10.1186/s12943-021-01442-3
   PubMed Web of Science ®Google Scholar
• Dumas G, Dufresne M, Asselin É, Girouard J, Carrier C, Reyes-Moreno C. CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion. Cancer Immunol Immunother. 2013;62(2):273–283. doi:10.1007/s00262-012-1333-2
   PubMed Web of Science ®Google Scholar
• Jia J, Wang Z, Li X, Wang Z, Wang X. Morphological characteristics and co-stimulatory molecule (CD80, CD86, CD40) expression in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 2012;160(2):223–227. doi:10.1016/j.ejogrb.2011.11.020
   PubMed Web of Science ®Google Scholar
• Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021;219:107709.
   PubMed Web of Science ®Google Scholar
• Yan C, Saleh N, Yang J, et al. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Mol Cancer. 2021;20(1):85.
   PubMed Web of Science ®Google Scholar